

Cover Story
NCI Director's Report
By Alexandria Carolan
As the likelihood of a flat budget increases for the 2024 fiscal year, NCI will have difficulty maintaining its current programs, the institute’s new director Kimryn Rathmell said in her inaugural NCI director’s report to members of the National Cancer Advisory Board Feb. 8.
In Brief


Drugs & Targets
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya